Avalo Therapeutics (AVTX) vs Ovid Therapeutics (OVID)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Ovid Therapeutics (OVID) has outperformed Avalo Therapeutics (AVTX) over the past year, gaining 57.1% versus a loss of 62.1%. Over five years, OVID leads with a -32.5% price change compared with -99.9% for AVTX. Ovid Therapeutics is the larger company by market cap ($415.2 million vs $390.9 million), about 1.1 times the size.
Ovid Therapeutics converts more of its revenue into profit, with a net margin of -240.1% versus -132642.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVTX | OVID |
|---|---|---|
| Share price | $6.76 | $2.20 |
| Market cap | $390.88M | $415.21M |
| 1-day change | +0.15% | -5.98% |
| YTD return | -62.78% | +34.97% |
| 1-year return | -62.09% | +57.14% |
| 5-year return | -99.89% | -32.52% |
| EPS (TTM) | $-2.26 | $-0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $59.00K | $7.25M |
| Revenue growth (YoY) | -86.62% | +1181.27% |
| Net income (latest FY) | $-78.26M | $-17.41M |
| Operating margin | -123601.69% | -585.20% |
| Net margin | -132642.37% | -240.13% |
| 52-week high | $24.27 | $3.11 |
| 52-week low | $6.53 | $1.26 |
| Distance from 52-week high | -72.15% | -29.15% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +414.79% | +179.55% |
| Average volume | 1.80M | 1.98M |
| Shares outstanding | 57.82M | 188.73M |
| Employees | 33 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OVID has outperformed AVTX by 119.2 percentage points over the past year.
- Ovid Therapeutics is more profitable, keeping -240.1 cents of every revenue dollar as net income versus -132642.4 cents for Avalo Therapeutics.
- Ovid Therapeutics grew revenue faster in its latest fiscal year (+1181.27% vs -86.62%).
About Avalo Therapeutics
AVTX stock →Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About Ovid Therapeutics
OVID stock →Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
AVTX vs OVID FAQ
Which is bigger, Avalo Therapeutics or Ovid Therapeutics?
Ovid Therapeutics (OVID) is larger, with a market capitalization of $415.21M compared with $390.88M for Avalo Therapeutics (AVTX).
Which stock has performed better over the past year, AVTX or OVID?
OVID returned +57.14% over the past 12 months, compared with -62.09% for AVTX (price return, excluding dividends). Past performance does not predict future results.
Are Avalo Therapeutics and Ovid Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.